Business Context and Reporting Period
This Form 8-K Current Report was filed by Natera, Inc. on December 2, 2024. The filing discloses the execution of an Amended and Restated Employment Agreement with Matthew Rabinowitz, Ph.D., the Company's Executive Chairman and Co-Founder. The agreement became effective on November 1, 2024, replacing prior agreements dated 2007, 2021, and 2023.
Key Financial Metrics
This filing does not contain financial performance data such as revenue, profit, cash flow, margins, debt, or liquidity. The document focuses exclusively on executive compensation terms.
Material Changes and Compensation Terms
The primary material change is the update to Dr. Rabinowitz's compensation structure, effective November 1, 2024:
- Base Salary: Set at 50% of the annual base salary of the Company's Chief Executive Officer (CEO).
- Cash Bonus: Eligible for an annual bonus up to 85% of base salary, contingent on performance goals established by the Board or Compensation Committee.
- Equity Awards: Entitled to annual long-term equity awards with a dollar value equal to 80% of the CEO's annual equity award value, subject to Board approval and vesting conditions matching the CEO's allocation.
Severance and Change in Control Provisions
The agreement outlines specific severance benefits upon involuntary termination:
- Standard Involuntary Termination:
- Lump-sum cash payment of 12 months' base salary.
- COBRA premium payments for up to 12 months.
- Accelerated vesting of time-based equity awards (greater of 50% of unvested shares or forward vesting for 12 months).
- Accelerated vesting of performance-based equity awards based on actual achievement multiplied by a service factor.
- Change in Control (CIC) Termination:
- Lump-sum cash payment increases to 18 months' base salary plus a full annual bonus (100% target).
- COBRA premium payments extend to 18 months.
- Full acceleration of time-based equity awards.
- Full acceleration of performance-based equity awards based on the greater of actual achievement or 100% achievement.
All severance benefits are contingent upon Dr. Rabinowitz executing a release agreement in favor of the Company.
Investor Verification Checklist
- Verify the current annual base salary of the CEO to calculate Dr. Rabinowitz's specific salary amount.
- Review the Company's 2015 Equity Incentive Plan for details on grant policies and procedures.
- Monitor the upcoming Form 10-K for the full text of the Amended and Restated Employment Agreement.
- Assess the impact of the 80% equity alignment on total shareholder dilution relative to the CEO's grants.